Cephalon, PsychoGenics Enter Neuro Pact

PsychoGenics and Cephalon have entered into a drug discovery agreement. Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.

The companies aim to jointly identify drug candidates suitable for clinical development. If Cephalon undertakes further development of the candidates, PsychoGenics will receive milestone payments and royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.

Dr. Emer Leahy, president and chief executive officer of PsychoGenics, said, “We are delighted to partner with Cephalon and look forward to a successful collaboration. We are confident that combining Cephalon’s and PsychoGenics’ complementary strengths and expertise will enable us to identify a new generation of treatments for neuropsychiatric disorders.”